MedTrace Logo

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

NCT00589628 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2013-08-26

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children. Participants (4-18 years of age) will be randomly assigned to either 5mg/kg or 10mg/kg dose of infliximab to be administered by intravenous infusion at four week intervals. Participant responses will be measured at at four to eight week intervals for up to ten months.

Conditions

  • Chronic Uveitis

Interventions

DRUG

infliximab

5mg/kg/dose IV at 4 week intervals

DRUG

infliximab

10mg/kg/dose IV at 4 week intervals

Sponsors & Collaborators

  • Childhood Arthritis and Rheumatology Research Alliance

    collaborator OTHER

  • Egla C. Rabinovich

    lead OTHER

Principal Investigators

  • Egla Rabinovich, MD. MPH · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589628 on ClinicalTrials.gov